Q1 FY 2027 saw robust revenue and EBITDA growth across all segments, with strong execution, higher capacity utilization, and disciplined investments driving profitability. Management reaffirmed full-year guidance and expects margin expansion, especially in CDMO, as overseas utilization improves.Bas…
Q1 FY 2027 saw 17% revenue growth and 72% EBITDA growth, with all segments contributing and margins expanding. CDMO and Complex Hospital Generics delivered strong results, supported by operational excellence, strategic investments, and robust order inflow.Based on Piramal Pharma Limited [PPLPHARMA…
MUMBAI, India, July 7, 2026 /CNW/ -- Piramal Pharma Limited (PPL) (NSE:PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, a…
